In an interview with Targeted Oncology, Richard S. Finn, MD, discussed the findings from the KEYNOTE-240 trial. He says that although these results were not statistically significant, they are still clinically meaningful.
In an interview with Targeted Oncology, Mark J. Levis, MD, PhD, discussed the findings from the follow-up analyses of the ADMIRAL trial that were presented at the 2019 ASCO Annual Meeting. He explained what these findings mean for the patient and what questions future research will aim to answer.
In an interview with Targeted Oncology, James Chih-Hsin Yang, MD discussed the updated findings from the FLAURA trial, which confirmed durable responses with frontline osimertinib in patients with EGFR-positive NSCLC. He highlighted what areas research will be focusing on in the coming years for patients harboring EGFR mutations.
In an interview with <em>Targeted Oncology</em>, Susan Branford, PhD discussed the current role of NGS testing in hematologic malignancies. Following her presentation at the 2019 EHA Congress, she addressed how NGS can be incorporated more into the community practice and what challenges must be overcome in order to make this happen.
In an interview with Targeted Oncology, David Spigel, MD, discussed the updated findings from the PACIFIC trial and how these data will impact the treatment landscape for patients with stage III NSCLC, as well as those with earlier-stage disease. He also highlighted controversies that clinicians face with incorporating immunotherapy into their practice for patients.
In June 2019, the FDA approved a number of agents many fields, including diffuse large B-cell lymphoma, head and neck squamous cell carcinoma, small cell lung cancer, gastroenteropancreatic neuroendocrine tumors, and multiple myeloma. The FDA also approved the fifth biosimilar for trastuzumab and another biosimilar for bevacizumab across several indications.
In an interview with <em>Targeted Oncology, </em>Richard T. Penson, MD, discussed the significance of the findings recently presented for the SOLO3 trial in patients with platinum-sensitive, relapsed <em>BRCA-</em>positive ovarian cancer.
In an interview with <em>Targeted Oncology, </em>Marina Kremyanskaya, MD, PhD, discussed the results from the phase II trial investigating the effects of CPI-0610 with or without ruxolitinib in patients with MF. Overall, the drug was well tolerated and effective in patients who had previously progressed on ruxolitinib or received inadequate responses to treatment.
Mitchell Smith, MD, PhD, discussed the most recent research and agents under investigation for the treatment of indolent lymphomas. He also highlighted how conversations transpire when discussing the watch-and-wait approach with his asymptomatic patients.
Charles G. Mullighan, MBBS, MSc, MD, discussed with <em>Targeted Oncology </em>the role of genetic variants in understanding a patient’s predisposition to ALL. He highlighted findings in research that may help in utilizing the current understanding of these genetic variants to make treatment decisions for patients with ALL.
In an interview with <em>Targeted Oncology</em>, Rory McCulloch, MD, discussed the results from a retrospective analysis for R-BAC treatment following relapse on a BTK inhibitor in patients with mantle cell lymphoma.
In an interview with <em>Targeted Oncology</em>, Kazuhiko Nakagawa, MD, PhD discussed the findings from the RELAY trial for the combination of ramucirumab plus erlotinib compared to erlotinib plus placebo. He suggested that these data could be practice-changing for the treatment of newly diagnosed patients with <em>EGFR</em>-positive NSCLC.<br />
In an interview with <em>Targeted Oncology, </em>Andrew X. Zhu, MD, PhD, FACP, discussed the results from the REACH-2 trial and the significance of the approval of ramucirumab monotherapy in patients with advanced HCC and high AFP levels who have previously failed sorafenib.
In an interview with <em>Targeted Oncology, </em>Phillipe Moreau, MD, discussed the findings from the phase III CASSIOPEIA trial and the potential role for daratumumab in patients with newly diagnosed multiple myeloma in combination with standard-of-care VTd before SCT.
<em>Targeted Oncology</em> spoke with experts in attendance at the 2019 ASCO Annual Meeting to review what they believed were some of the biggest takeaways from this year's presentation across the fields of lung cancer, breast cancer, GI cancers, genitourinary cancers, melanoma, and multiple myeloma.
In an interview with <em>Targeted Oncology, </em>Emese Zsiros, MD, PhD, discussed the findings from this phase II trial investigating the triplet regimen in patients with recurrent disease. In addition, she shared details for the next steps planned for this regimen.
In an interview with <em>Targeted Oncology</em>, Paul L. Crispen, MD, discussed several ongoing trials for patients with bladder cancer focused on the importance of bladder preservation. He also highlighted a clinical trial currently enrolling at the University of Florida Health for patients with upper tract disease.
In an interview with <em>Targeted Oncology</em>, Naval G. Daver, MD, discussed the possibility of combination therapy in patients with AML. He highlights some of the most recent data to come out for this patient population, including for those harboring a <em>TP53</em> or <em>FLT3</em> mutation.
According to the latest Annual Report to the Nation on the Status of Cancer, cancer death rates have declined in men, women, and children across all cancer types, and have continued to decline between 1999 and 2016. In a special section of this year’s report, however, data show that both cancer incidence and death rates were higher in women aged 20 to 49 compared to male counterparts.
A look back at all the FDA news that happened in the month of May 2019, including several new approvals, orphan drug designations, breakthrough therapy designations, fast track designations, and more.
Aziz Nazha, MD, discusses the different agents being explored for patients who have progressed on ruxolitinib, and why this is a significant unmet need. He also highlights the role of genetics in patients with MF and how a better understanding can help guide treatment decisions.
In an interview with <em>Targeted Oncology</em>, experts in gynecology, gastrointestinal, genitourinary, lung, and breast cancers spoke to the significance of the abstracts they are most looking forward to at the 2019 ASCO Annual Meeting.
Rami S. Komrokji, MD, explains the diagnostic and molecular workup behind myeloproliferative neoplasm diagnoses and discusses treatment options based on the case scenario of a patient with myelofibrosis.
Raajit K. Rampal, MD, PhD, discusses a retrospective analysis of pre-transplant samples from patients with MF to determine the value of mutational profiling in predicting outcomes after transplant.
Rozita Yarmand, PhD, discusses the rationale for investigating ONC201 in patients with medullary thyroid cancer and the toxicity profile that has been seen with this small molecule in mouse models and in other tumor types.
Pashtoon M. Kasi, MD, MBBS, MS, discussed the current role of liquid biopsies in patients with CRC, GI, and other types of cancers. He also highlights the advantages to making treatment decisions based on results from liquid biopsies.
Jennifer Geurts, MS, CGC, discusses the current role of genetic testing, both in patients diagnosed with cancer, as well as family members that could be at risk of developing cancer. She also highlights how genetic counseling can impact treatment decisions in patients with pancreatic, breast, and ovarian cancers.
Updated NCCN guidelines in prostate cancer recommend integration of tumor genetic testing into clinical practice for patients with advanced prostate cancer. For patients with regional or metastatic disease, the guidelines recommend testing for homologous recombination gene mutations and for microsatellite instability or mismatch repair deficiency, according to Emmanuel S. Antonarakis, MBBCh.
Geoffrey R. Oxnard, MD, discusses testing error underlying liquid biopsy discordance. He also highlights steps clinicians can take to optimize liquid biopsies and where he sees this evolving in the treatment landscape for patients with cancer.
According to results from a phase IIIb interim analysis, afatinib demonstrated a predictable and manageable toxicity profile and promising efficacy in patients with <em>EGFR</em> mutation-positive non–small cell lung cancer.